China’s generic-drugs market opens up opportunities for the global industry

Strategic options for large pharma companies to navigate patent cliffs

Patent Cliff: Can small healthcare firms dictate terms for bigger Pharma on the M&A deals?

US 2Q 2024 earnings wrap: Nvidia tempers AI bull run

US 4Q23 earnings wrap: The AI bull rages on

Big pharma’s bet on biotech – key drivers and top focus areas for M&A

The immuno-oncology market – segments, challenges and trends

Consumer healthcare and the pandemic: Trends that will likely drive industry growth